 CARLSBAD, Calif., Sept. 08, 2021 GLOBE NEWSWIRE -- Qualigen Therapeutics, Inc. NASDAQ: QLGN, a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. 